Equities research analysts expect Portola Pharmaceuticals (NASDAQ:PTLA) to report earnings per share (EPS) of ($1.46) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Portola Pharmaceuticals’ earnings, with estimates ranging from ($1.49) to ($1.42). Portola Pharmaceuticals reported earnings per share of ($0.74) during the same quarter last year, which indicates a negative year over year growth rate of 97.3%. The company is expected to issue its next earnings report on Monday, May 14th.
On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($4.74) per share for the current fiscal year, with EPS estimates ranging from ($5.08) to ($4.32). For the next financial year, analysts forecast that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($2.08) to ($0.44). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. The business had revenue of $9.80 million for the quarter, compared to the consensus estimate of $3.71 million. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The company’s quarterly revenue was down 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) EPS.
Portola Pharmaceuticals stock traded down $1.40 during trading hours on Wednesday, hitting $31.26. 543,060 shares of the stock traded hands, compared to its average volume of 1,260,358. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.92 and a current ratio of 5.94. The company has a market cap of $2,135.71, a PE ratio of -6.50 and a beta of 1.50. Portola Pharmaceuticals has a 1 year low of $30.10 and a 1 year high of $67.10.
In other news, EVP Tao Fu sold 1,135 shares of the company’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $38.47, for a total value of $43,663.45. Following the sale, the executive vice president now owns 18,346 shares in the company, valued at $705,770.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Oppenheimer Asset Management Inc. boosted its stake in shares of Portola Pharmaceuticals by 251.2% in the third quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 2,047 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Portola Pharmaceuticals by 54.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 1,141 shares during the last quarter. Penbrook Management LLC purchased a new stake in shares of Portola Pharmaceuticals in the fourth quarter worth about $209,000. Sei Investments Co. acquired a new position in Portola Pharmaceuticals in the 3rd quarter worth about $217,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Portola Pharmaceuticals in the 3rd quarter worth about $218,000. Hedge funds and other institutional investors own 88.44% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$1.46 Earnings Per Share Expected for Portola Pharmaceuticals (PTLA) This Quarter” was first reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.wkrb13.com/2018/04/02/1-46-earnings-per-share-expected-for-portola-pharmaceuticals-ptla-this-quarter.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.